Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group
Authors: D. Mandelker, M. Donoghue, S. Talukdar, M.F. Berger, B.S. Taylor, C. Turnbull
Show all authors
It is increasingly common in oncology practice to perform tumour sequencing using large cancer panels. For pathogenic sequence variants in cancer susceptibility genes identified on tumour-only sequencing, it is often unclear whether they are of somatic or constitutional (germline) origin. There is wide-spread disparity regarding both the extent to which systematic ‘germline-focussed analysis’ is carried out upon tumour sequencing data and for which variants follow-up analysis of a germline sample is carried out.
Here we present analyses of paired sequencing data from 17152 cancer samples, in which 1494 pathogenic sequence variants were identified across 65 cancer susceptibility genes.
From these analyses, the European Society of Medical Oncology Precision Medicine Working Group Germline Subgroup has generated (i) recommendations regarding germline-focussed analyses of tumour-only sequencing data, (ii) indications for germline follow-up testing and (iii) guidance on patient information-giving and consent.